candesartan in heart failure l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Candesartan in Heart Failure PowerPoint Presentation
Download Presentation
Candesartan in Heart Failure

Loading in 2 Seconds...

play fullscreen
1 / 8

Candesartan in Heart Failure - PowerPoint PPT Presentation


  • 337 Views
  • Uploaded on

CHARM Trial. Candesartan in Heart Failure. Presented at European Society of Cardiology 2003. CHARM Trial. 7,601 patients with heart failure 3 Individual component randomized trials with the ARB candesartan (4 or 8 mg/day, titrated to target dose of 32 mg) or placebo . CHARM Preserved

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Candesartan in Heart Failure' - sandra_john


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
candesartan in heart failure

CHARM Trial

Candesartan in Heart Failure

Presented at

European Society of Cardiology 2003

charm trial
CHARM Trial

7,601 patients with heart failure

3 Individual component randomized trials with the ARB candesartan (4 or 8 mg/day, titrated to target dose of 32 mg) or placebo

  • CHARM Preserved
  • Patients with LVEF >40% with or without ACE-inhibitor
  • CHARM Added
  • Patients with LVEF <40% and treated with an ACE-inhibitor
  • CHARM Alternative
  • Patients with LVEF <40% and ACE-inhibitor intolerant
  • Endpoints (follow-up minimum 2 years):
    • Primary – Component trials: cardiovascular mortality or CHF hospitalization
    • Primary – Overall trial results: All-cause mortality

European Society of Cardiology 2003

charm overall program
CHARM Overall Program

CV Mortality orCHF Hospitalization

HR 0.84

p<0.0001

All-cause mortality

HR 0.91

95% CI 0.83-1.00

p=0.055

European Society of Cardiology 2003

charm added trial
CHARM Added Trial

CV Mortality

HR 0.84

p=0.02

CV Mortality or

CHF hospitalization

HR 0.85

p=0.011

European Society of Cardiology 2003

charm alternative trial
CHARM Alternative Trial

CV Mortality or

CHF hospitalization

HR 0.77

p=0.0004

CV Mortality

HR 0.85

p=0.072

European Society of Cardiology 2003

charm preserved trial
CHARM Preserved Trial

CV Mortality or

CHF hospitalization

HR 0.89

p=0.118

CV Mortality

HR 0.99

p=0.918

European Society of Cardiology 2003

charm trial7
CHARM Trial
  • CHARM Overall: Among symptomatic heart failure patients, treatment with ARB candesartan was associated with lower CV mortality and a trend toward lower all-cause mortality compared with placebo
  • CHARM Added: Among patients with symptomatic heart failure and an ejection fraction <40% treated with an ACE-inhibitor, additional treatment with the ARB candesartan was associated with reduction in the primary endpoint of cardiovascular death or heart failure hospitalizations
charm trial8
CHARM Trial
  • CHARM Alternative: Among patients with symptomatic heart failure and an ejection fraction <40% who were ACE-inhibitor intolerant, treatment with the ARB candesartan was associated with reduction in the primary endpoint of cardiovascular death or heart failure hospitalizations
  • CHARM Preserved: Among patients with symptomatic heart failure and an ejection fraction >40%, treatment with the ARB candesartan was associated with a non-significant reduction in the primary endpoint of cardiovascular death or heart failure hospitalizations